drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic, off-the-shelf induced pluripotent stem cell–derived natural killer cells engineered with a chimeric antigen receptor targeting CLL1 (CLEC12A) on AML blasts to redirect NK recognition and trigger cytotoxic killing via perforin/granzyme and death-receptor pathways while sparing normal hematopoietic stem cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic iPSC-derived natural killer cells engineered with a chimeric antigen receptor targeting CLL1 (CLEC12A) on AML blasts, redirecting NK recognition to CLL1-positive leukemic cells and inducing cytotoxic killing via perforin/granzyme release and death receptor pathways (e.g., FasL/TRAIL), with intent to spare normal hematopoietic stem cells due to low/absent CLL1 expression.
drug_name
iPSC-derived CAR-NK cells (anti-CLL1)
nct_id_drug_ref
NCT06367673